News for 'drug money'

Is the ruling body of athletics protective of drug cheats?

Is the ruling body of athletics protective of drug cheats?

Rediff.com26 Mar 2016

The IAAF ruling body of athletics is proactive in tackling doping and not protective of drug cheats, according to president Sebastian Coe.

MRP excise duty to hit drug cos

MRP excise duty to hit drug cos

Rediff.com11 Jan 2005

The government's decision to impose excise duty on the maximum retail price of all drugs -- which took effect from January 8 -- may have an adverse impact on the domestic operations of drug makers, said analysts.

Post takeover, Sun Pharma to rebrand Ranbaxy drugs in the US

Post takeover, Sun Pharma to rebrand Ranbaxy drugs in the US

Rediff.com9 Apr 2014

Ranbaxy drugs sold in the United States will be gradually rebranded as Sun Pharma treatments

Pharma, consumer durables sectors likely to feel China curb heat

Pharma, consumer durables sectors likely to feel China curb heat

Rediff.com12 Dec 2022

The pharmaceutical and the consumer durables sectors, which depend on China for imports, have not been impacted yet due to unrest in China with people protesting against lockdowns. But the lockdown could have an impact on the supply of components used in consumer durables if it continues for the next fortnight. In the pharmaceutical industry, Indian players import 66-70 per cent of their bulk drug requirements from China.

Drug makers may fall under NDPS Act

Drug makers may fall under NDPS Act

Rediff.com27 Nov 2007

In a reversal of its two-year-old decision to avoid from the purview of the Narcotic Drugs and Psychotropic Substances (NDPS) Act, 1985, the finance ministry, which administers the Act, has once again proposed compulsory registration of all medicine manufacturers and dealers that handle drugs that contain narcotic and psychotropic substances before the Central Bureau of Narcotics (CBN). CBN comes under the revenue department of the ministry.

28% tax to be levied on turnover of online gaming firms

28% tax to be levied on turnover of online gaming firms

Rediff.com11 Jul 2023

The panel, headed by the Union finance minister and comprising of representatives of all states and UTs, decided on tax rate based on recommendation of a group of ministers that looked at taxing casinos, horse racing and online gaming.

Cipla's petition against drug price revision rejected

Cipla's petition against drug price revision rejected

Rediff.com19 Apr 2013

The department of pharmaceuticals turned down a review petition by drugmaker Cipla against a price fixation order by the National Pharmaceutical Pricing Authority, slashing the price of Dytor Plus, a medicine for kidney and heart ailments.

NPIL in cancer drug discovery pact with Merck

NPIL in cancer drug discovery pact with Merck

Rediff.com20 Nov 2007

The company is demerging its new chemical entity research unit into a separate company to meet the demands of increased spend on research and development, and to insulate investors from the risks involved. According to the deal signed with Merck, NPIL will discover and develop new drugs for two selected targets provided by Merck in the area of cancer.

Alembic to expand bulk drugs business in US

Alembic to expand bulk drugs business in US

Rediff.com22 May 2003

Indian drug maker Alembic Ltd plans to expand its bulk drugs business in the United States by joining hands with US formulations makers, the Bombay Stock Exchange said on Thursday.

Indian drug makers maintain pace of US mktg nod

Indian drug makers maintain pace of US mktg nod

Rediff.com4 Jan 2010

This increase is despite the decreased growth of drug sales in the US - the world's largest market - which has seen a tightening of regulations and aggressive competition.

New drug policy welcome move: Pharma companies

New drug policy welcome move: Pharma companies

Rediff.com20 May 2013

Last week, the Department of Pharmaceuticals had notified the Drugs (Prices Control) Order 2013 under which prices of 348 medicines in the National List of Essential Medicines (NLEM) have been brought.

Ranbaxy to develop prostrate cancer drug

Ranbaxy to develop prostrate cancer drug

Rediff.com24 Jun 2004

Ranbaxy said on Thursday that it has signed an exclusive licensing agreement with US-based Atrix Laboratories to develop and market prostrate cancer drug Eligard in India.

Lupin launches generic GERD drug in the US market

Lupin launches generic GERD drug in the US market

Rediff.com11 Nov 2013

The company's US-based subsidiary Lupin Pharmaceuticals Inc has launched its generic Rabeprazole Sodium delayed-release tablets, 20 mg in the American market after having received approval to market it from the US Food and Drug Administration, according to a statement by Lupin.

Ranbaxy gets US FDA nod for drug

Ranbaxy gets US FDA nod for drug

Rediff.com15 Mar 2004

Ranbaxy Laboratories on Monday said it has received tentative approval from the United States Food and Drug Administration to manufacture and market anti-hypertension drug Quinapril Hydrochloride in the US.

GoM tweaks stand on drug pricing

GoM tweaks stand on drug pricing

Rediff.com22 Nov 2012

Sharad Pawar says final draft will go to Cabinet before Tuesday.

Now, drug prices may be capped at time of launch

Now, drug prices may be capped at time of launch

Rediff.com1 Apr 2013

The idea is to ensure drug companies do not gold-plate drugs to exorbitantly raise prices while introducing those in the market.

Prices of key drugs to be cut by up to half

Prices of key drugs to be cut by up to half

Rediff.com17 Jun 2013

The National Pharmaceutical Pricing Authority will soon notify prices of as many as 150 packs of essential medicines in line with the new pharma pricing policy, according to official sources.

Himachal drug units rush to register new products

Himachal drug units rush to register new products

Rediff.com29 Mar 2010

Pharmaceutical companies in Himachal Pradesh are queuing up to register new products at the drugs controller's office before the seven-year tax holiday window for hill states ends on March 31

Sameer Wankhede's eventful NCB stint to end on Dec 31

Sameer Wankhede's eventful NCB stint to end on Dec 31

Rediff.com17 Dec 2021

The tenure of Indian Revenue Service officer Sameer Wankhede with the Narcotics Control Bureau, which was marked by controversy, would end on December 31, official sources said on Friday.

« Prev  |